CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10367720" target="_blank" >RIV/00216208:11140/18:10367720 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/18:10367720

Result on the web

<a href="http://dx.doi.org/10.21873/anticanres.12245" target="_blank" >http://dx.doi.org/10.21873/anticanres.12245</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12245" target="_blank" >10.21873/anticanres.12245</a>

Result language

angličtina

Original language name

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer

Original language description

Aim: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery. Patients and Methods: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 712 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. Results: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p&lt;0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. Conclusion: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

38

Issue of the periodical within the volume

1

Country of publishing house

GR - GREECE

Number of pages

5

Pages from-to

465-469

UT code for WoS article

000419130100062

EID of the result in the Scopus database

2-s2.0-85039801076